Is Venus MedTech HangZhou stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Venus MedTech HangZhou 10 years ago, but if you had invested on Tuesday 10th of December 2019 when the price was HKD43.05, you would have made a loss of HKD-37.43 per share or -86.95%
We do not have enough data to give you this answer.
Venus MedTech HangZhou has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Venus MedTech HangZhou to be high [0.85 of 1]
US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.